###begin article-title 0
###xml 8 19 8 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 56 61 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Role of CCL3L1-CCR5 Genotypes in the Epidemic Spread of HIV-1 and Evaluation of Vaccine Efficacy
###end article-title 0
###begin p 1
Conceived and designed the experiments: HK MJD SKA. Performed the experiments: MJD. Analyzed the data: HK MJD SKA. Contributed reagents/materials/analysis tools: HK. Wrote the paper: HK SKA. Conducted statistical analyses: HK. Provided critical conceptual input and helped with the writing of the paper: VM BA CM GC RAC. Provided samples from Cameroon: CM.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 48 51 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 90 93 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 137 140 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 266 269 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Polymorphisms in CCR5, the major coreceptor for HIV, and CCL3L1, a potent CCR5 ligand and HIV-suppressive chemokine, are determinants of HIV-AIDS susceptibility. Here, we mathematically modeled the potential impact of these genetic factors on the epidemic spread of HIV, as well as on its prevention.
###end p 3
###begin title 4
Methods and Results
###end title 4
###begin p 5
###xml 0 2 0 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ro</italic>
###xml 194 196 194 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ro</italic>
###xml 325 336 325 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 347 349 347 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ro</italic>
###xml 435 446 435 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 547 553 547 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1</italic>
###xml 579 583 579 583 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5</italic>
###xml 645 647 645 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pc</italic>
###xml 849 860 849 860 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 889 891 889 891 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pc</italic>
###xml 972 983 972 983 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 1124 1135 1124 1135 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 1267 1278 1267 1278 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 156 159 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 161 164 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 263 266 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 609 612 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Ro, the basic reproductive number, is a fundamental concept in explaining the emergence and persistence of epidemics. By modeling sexual transmission among HIV+/HIV- partner pairs, we find that Ro estimates, and concordantly, the temporal and spatial patterns of HIV outgrowth are highly dependent on the infecting partners' CCL3L1-CCR5 genotype. Ro was least and highest when the infected partner possessed protective and detrimental CCL3L1-CCR5 genotypes, respectively. The modeling data indicate that in populations such as Pygmies with a high CCL3L1 gene dose and protective CCR5 genotypes, the spread of HIV might be minimal. Additionally, Pc, the critical vaccination proportion, an estimate of the fraction of the population that must be vaccinated successfully to eradicate an epidemic was <1 only when the infected partner had a protective CCL3L1-CCR5 genotype. Since in practice Pc cannot be >1, to prevent epidemic spread, population groups defined by specific CCL3L1-CCR5 genotypes might require repeated vaccination, or as our models suggest, a vaccine with an efficacy of >70%. Further, failure to account for CCL3L1-CCR5-based genetic risk might confound estimates of vaccine efficacy. For example, in a modeled trial of 500 subjects, misallocation of CCL3L1-CCR5 genotype of only 25 (5%) subjects between placebo and vaccine arms results in a relative error of approximately12% from the true vaccine efficacy.
###end p 5
###begin title 6
Conclusions
###end title 6
###begin p 7
###xml 0 11 0 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 156 158 156 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ro</italic>
###xml 211 222 211 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 376 387 376 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 56 59 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 138 141 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 471 476 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
CCL3L1-CCR5 genotypes may impact on the dynamics of the HIV epidemic and, consequently, the observed heterogeneous global distribution of HIV infection. As Ro is lowest when the infecting partner has beneficial CCL3L1-CCR5 genotypes, we infer that therapeutic vaccines directed towards reducing the infectivity of the host may play a role in halting epidemic spread. Further, CCL3L1-CCR5 genotype may provide critical guidance for optimizing the design and evaluation of HIV-1 vaccine trials and prevention programs.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 675 678 675 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Anderson1">[1]</xref>
###xml 680 683 680 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Blower1">[2]</xref>
###xml 685 688 685 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Cohen1">[3]</xref>
###xml 807 810 807 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Anderson1">[1]</xref>
###xml 812 815 812 815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Blower1">[2]</xref>
###xml 817 820 817 820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Cohen1">[3]</xref>
###xml 822 825 822 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Quinn1">[4]</xref>
###xml 827 830 827 830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Gray1">[5]</xref>
###xml 832 835 832 835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Gilbert1">[6]</xref>
###xml 1007 1010 1007 1010 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Dean1">[7]</xref>
###xml 1012 1015 1012 1015 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Samson1">[8]</xref>
###xml 1017 1020 1017 1020 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Zimmerman1">[9]</xref>
###xml 1022 1026 1022 1026 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-McDermott1">[10]</xref>
###xml 1028 1032 1028 1032 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Martin1">[11]</xref>
###xml 1034 1038 1034 1038 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Winkler1">[12]</xref>
###xml 1040 1044 1040 1044 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Gonzalez1">[13]</xref>
###xml 1046 1050 1046 1050 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-An1">[14]</xref>
###xml 1052 1056 1052 1056 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Mangano1">[15]</xref>
###xml 1058 1062 1058 1062 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Gonzalez2">[16]</xref>
###xml 1064 1068 1064 1068 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Gonzalez3">[17]</xref>
###xml 1070 1074 1070 1074 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Winkler2">[18]</xref>
###xml 1076 1080 1076 1080 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Gao1">[19]</xref>
###xml 1082 1086 1082 1086 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Gonzalez4">[20]</xref>
###xml 1088 1092 1088 1092 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Fellay1">[21]</xref>
###xml 1094 1098 1094 1098 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Martin2">[22]</xref>
###xml 1100 1104 1100 1104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-An2">[23]</xref>
###xml 1121 1125 1121 1125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-OBrien1">[24]</xref>
###xml 1127 1131 1127 1131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Nolan1">[25]</xref>
###xml 1133 1137 1133 1137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Kaslow1">[26]</xref>
###xml 1139 1143 1139 1143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Hunt1">[27]</xref>
###xml 1145 1149 1145 1149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Telenti1">[28]</xref>
###xml 1151 1155 1151 1155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Hutcheson1">[29]</xref>
###xml 1505 1508 1505 1508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Cohen1">[3]</xref>
###xml 1510 1514 1510 1514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-AsamoahOdei1">[30]</xref>
###xml 1516 1520 1516 1520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Buve1">[31]</xref>
###xml 1522 1526 1522 1526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Pepin1">[32]</xref>
###xml 1528 1532 1528 1532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Ferry1">[33]</xref>
###xml 1534 1538 1534 1538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Buve2">[34]</xref>
###xml 1540 1544 1540 1544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Buve3">[35]</xref>
###xml 1546 1550 1546 1550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Mokili1">[36]</xref>
###xml 1552 1556 1552 1556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Mulanga1">[37]</xref>
###xml 1558 1562 1558 1562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-KinoshitaMoleka1">[38]</xref>
###xml 2052 2056 2052 2056 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Cohen2">[39]</xref>
###xml 2058 2062 2058 2062 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Moore1">[40]</xref>
###xml 2064 2068 2064 2068 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Johnston1">[41]</xref>
###xml 2070 2074 2070 2074 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Fauci1">[42]</xref>
###xml 2076 2080 2076 2080 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Walker1">[43]</xref>
###xml 2082 2086 2082 2086 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Steinbrook1">[44]</xref>
###xml 24 29 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 66 71 <span type="species:ncbi:9606">human</span>
###xml 296 301 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 363 366 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 532 535 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 611 618 <span type="species:ncbi:9606">persons</span>
###xml 646 649 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 668 674 <span type="species:ncbi:9606">person</span>
###xml 982 985 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1268 1271 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1378 1381 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1483 1486 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1748 1751 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1951 1954 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 2038 2041 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
For more than 25 years, HIV-1 infection has been spreading across human populations relentlessly. An improved understanding of the factors that promote viral spread and an effective vaccine is required to halt this pandemic. Significant attention has been placed on elucidating the impact of the HIV-1 genotype on the spread of infection and on development of an HIV vaccine. Although much less is known about the impact of host factors on these events, several reasons suggest that their contribution might be large. The spread of HIV in the general population is a product of the susceptibility of uninfected persons and the communicability of HIV from the infected person [1], [2], [3]. This communicability is, in part, reflected by infectivity of the host as measured by the plasma RNA viral load (VL) [1], [2], [3], [4], [5], [6]. However, we and others have demonstrated that susceptibility and communicability are dictated, in part, by polymorphisms in genes that influence HIV-AIDS susceptibility ([7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18], [19], [20], [21], [22], [23] and reviewed in [24], [25], [26], [27], [28], [29]). For this reason, we hypothesized that the inherent variability among individuals in host genes that influence HIV-AIDS susceptibility, when translated to the level of a population, might influence the epidemic spread of HIV in that population and, by extension, might contribute to the observed heterogeneous distribution of HIV among populations [3], [30], [31], [32], [33], [34], [35], [36], [37], [38]. We also posited that if evidence in support of this hypothesis were to be found, it might have implications for the possibility that failure to account for host factors that influence HIV-AIDS susceptibility may pose a challenge in designing public health measures to curb the epidemic, including evaluation of the efficacy of a vaccine. This was relevant in light of data from a recent HIV vaccine trial where vaccination was associated with an increased risk of acquiring HIV infection [39], [40], [41], [42], [43], [44].
###end p 9
###begin p 10
###xml 130 134 130 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Berger1">[45]</xref>
###xml 136 140 136 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Lederman1">[46]</xref>
###xml 243 247 243 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Nibbs1">[47]</xref>
###xml 249 253 249 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Townson1">[48]</xref>
###xml 255 259 255 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Xin1">[49]</xref>
###xml 261 265 261 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Aquaro1">[50]</xref>
###xml 267 271 267 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Struyf1">[51]</xref>
###xml 273 277 273 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Menten1">[52]</xref>
###xml 348 354 348 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1</italic>
###xml 409 413 409 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5</italic>
###xml 635 639 635 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Dolan1">[53]</xref>
###xml 657 660 657 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Dean1">[7]</xref>
###xml 662 665 662 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Samson1">[8]</xref>
###xml 667 670 667 670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Zimmerman1">[9]</xref>
###xml 672 676 672 676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Gonzalez4">[20]</xref>
###xml 678 682 678 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-MeddowsTaylor1">[54]</xref>
###xml 684 688 684 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Kuhn1">[55]</xref>
###xml 690 694 690 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Nakajima1">[56]</xref>
###xml 696 700 696 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Sadam1">[57]</xref>
###xml 918 922 918 922 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Gonzalez4">[20]</xref>
###xml 924 928 924 928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Dolan1">[53]</xref>
###xml 930 934 930 934 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Ahuja1">[58]</xref>
###xml 1052 1055 1052 1055 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Dean1">[7]</xref>
###xml 1057 1060 1057 1060 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Samson1">[8]</xref>
###xml 1062 1066 1062 1066 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-McDermott1">[10]</xref>
###xml 1068 1072 1068 1072 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Martin1">[11]</xref>
###xml 1074 1078 1074 1078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Gonzalez1">[13]</xref>
###xml 1080 1084 1080 1084 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-An1">[14]</xref>
###xml 1086 1090 1086 1090 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Mangano1">[15]</xref>
###xml 1092 1096 1092 1096 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Gonzalez4">[20]</xref>
###xml 1098 1102 1098 1102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-OBrien1">[24]</xref>
###xml 1104 1108 1104 1108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Nolan1">[25]</xref>
###xml 1110 1114 1110 1114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Kaslow1">[26]</xref>
###xml 1116 1120 1116 1120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Hunt1">[27]</xref>
###xml 1122 1126 1122 1126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Telenti1">[28]</xref>
###xml 1128 1132 1128 1132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Dolan1">[53]</xref>
###xml 1134 1138 1134 1138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Ahuja1">[58]</xref>
###xml 1181 1185 1181 1185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Ahuja1">[58]</xref>
###xml 1187 1191 1187 1191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Valdez1">[59]</xref>
###xml 1193 1197 1193 1197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-OBrien2">[60]</xref>
###xml 1199 1203 1199 1203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Hendrickson1">[61]</xref>
###xml 1270 1276 1270 1276 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1</italic>
###xml 1374 1378 1374 1378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Kuhn1">[55]</xref>
###xml 1380 1384 1380 1384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Shalekoff1">[62]</xref>
###xml 1418 1424 1418 1424 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1</italic>
###xml 1439 1443 1439 1443 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5</italic>
###xml 1582 1586 1582 1586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Dolan1">[53]</xref>
###xml 1588 1592 1588 1592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Kulkarni1">[63]</xref>
###xml 115 118 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 217 220 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 596 599 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 641 644 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 893 896 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1330 1333 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1719 1722 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
We selected two candidate genes to test our hypotheses: those coding for CC chemokine receptor 5 (CCR5), the major HIV coreceptor [45], [46], and CC chemokine ligand 3-like 1 (CCL3L1), the most potent CCR5 ligand and HIV-suppressive chemokine [47], [48], [49], [50], [51], [52]. In previous studies, we and others found that the copy number of the CCL3L1-containing segmental duplications and/or genotypes of CCR5 were determinants of inter-individual differences in several parameters: cell-mediated immunity (CMI) as assessed by delayed-type hypersensitivity (DTH) skin test reactivity in both HIV-negative and -positive individuals [53]; HIV acquisition [7], [8], [9], [20], [54], [55], [56], [57]; events established during the early stages of the infection such as the magnitude of initial CD4+ T-cell depletion and the extent of viral replication as reflected by the steady-state plasma HIV RNA VL (VL setpoint) [20], [53], [58]; rate and extent of CD4+ T cell depletion during disease course and, consequently, risk and rate of AIDS development [7], [8], [10], [11], [13], [14], [15], [20], [24], [25], [26], [27], [28], [53], [58] and recovery of CD4+ T cells during HAART [58], [59], [60], [61]. Others have also found a relationship between the copy number of CCL3L1-containing segmental duplications and viral load and HIV-specific CD4+ and CD8+ T cell responses [55], [62]. However, we also found that the CCL3L1 gene dose and CCR5 genotypes affected risk and rate of developing AIDS independent of their effects on the VL or CMI as assessed by DTH skin test reactivity [53], [63]. The latter findings indicated that only a portion of the disease-modifying effects associated with these two host factors on HIV-AIDS susceptibility can be captured by assessing the plasma VL or a surrogate marker of CMI. The nature of these unmeasured effects is currently unknown.
###end p 10
###begin p 11
###xml 223 226 223 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Cohen1">[3]</xref>
###xml 228 232 228 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Wawer1">[64]</xref>
###xml 289 293 289 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Gandhi1">[65]</xref>
###xml 438 449 438 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 821 832 821 832 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 962 973 962 973 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 338 341 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 481 484 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 545 552 <span type="species:ncbi:9606">patient</span>
###xml 645 648 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 901 904 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Factors that influence the magnitude of the events that are established during the early stages of infection have important public health relevance, as the rate of transmission is highest during this phase of the infection [3], [64]. Furthermore, CMI is a critical antiviral host response [65]. Thus, we surmised that by affecting CMI in HIV-negative and -positive individuals, viral entry, early events, and other unmeasured parameters, CCL3L1-CCR5 genotypes might affect risk of HIV acquisition and disease progression rates for an individual patient, while at the level of populations they might modify the propagation and maintenance of the HIV pandemic and consequently, they may impact on preventive interventions. To examine this possibility, we used modeling approaches to determine whether genetic variations in CCL3L1-CCR5 can serve as a biological basis for distinct subtrajectories of the HIV epidemic in a population, and whether accounting for the CCL3L1-CCR5 genetic makeup of vaccine trials could provide a more precise estimate of the critical proportion of the population-based vaccination coverage required to limit the epidemic, as well as vaccine efficacy.
###end p 11
###begin title 12
Results
###end title 12
###begin title 13
Modeled impact of CCL3L1-CCR5 genetic risk groups (GRG) on the epidemic
###end title 13
###begin p 14
###xml 52 58 52 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1</italic>
###xml 66 69 66 69 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">low</sup>
###xml 60 69 60 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1<sup>low</sup></italic>
###xml 79 83 79 83 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 73 83 73 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1<sup>high</sup></italic>
###xml 119 123 119 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5</italic>
###xml 139 142 139 142 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">det</sup>
###xml 135 142 135 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5<sup>det</sup></italic>
###xml 151 158 151 158 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">non-det</sup>
###xml 147 158 147 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5<sup>non-det</sup></italic>
###xml 226 230 226 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Gonzalez4">[20]</xref>
###xml 411 415 411 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Gonzalez4">[20]</xref>
###xml 499 508 499 508 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1a</bold>
###xml 499 508 499 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003671-g001"><bold>Figure 1a</bold></xref>
###xml 510 514 510 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Dolan1">[53]</xref>
###xml 516 520 516 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Ahuja1">[58]</xref>
###xml 378 381 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Based on possession of a low or high copy number of CCL3L1 (CCL3L1low or CCL3L1high) and detrimental or nondetrimental CCR5 genotypes (CCR5det and CCR5non-det) we assigned the polymorphisms in these two genes into four groups [20]. Based on their associations with a low, moderate and high risk for disease progression rates to AIDS and death in a portion of the U.S.-based DoD HIV Natural History Study cohort [20], we designated these genotypes as low, moderate and high genetic risk groups (GRG; Figure 1a) [53], [58].
###end p 14
###begin title 15
###xml 26 37 26 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 105 108 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Conceptual model by which CCL3L1-CCR5 genotypes might influence the prevention and epidemic outgrowth of HIV infection.
###end title 15
###begin p 16
###xml 64 70 64 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1</italic>
###xml 102 106 102 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5</italic>
###xml 284 286 284 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pc</italic>
###xml 402 404 402 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ro</italic>
###xml 406 407 406 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">e</italic>
###xml 412 413 412 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f</italic>
###xml 478 511 478 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003671.s001">Supplementary Online Materials S1</xref>
###xml 533 541 533 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003671.s002">Table S1</xref>
###xml 664 666 664 666 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pc</italic>
###xml 695 698 695 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Anderson1">[1]</xref>
###xml 710 713 710 713 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Blower1">[2]</xref>
###xml 772 783 772 783 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 809 813 809 813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Dolan1">[53]</xref>
###xml 815 819 815 819 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Kulkarni1">[63]</xref>
(a) Classification system used to categorize the copy number of CCL3L1 (low or high) and genotypes of CCR5 (detrimental or nondetrimental) into three (low, moderate and high) risk categories. (b) Conceptual model by which the GRGs might affect epidemiological endpoints. The endpoint Pc has different components, and those that might be influenced by the GRGs are shown in green-colored letters, i.e., Ro, e and f. The model assumptions, parameters and methods are described in Supplementary Online Materials S1 (SOM), section 1 and Table S1. The conceptual model assumes a vaccine that requires the induction of CMI, in part, for protection. Here, the formula of Pc is from studies by Anderson [1] and Blower [2]. ?, indicates possible additional effects associated with CCL3L1-CCR5 GRGs that are unmeasured [53], [63].
###end p 16
###begin p 17
###xml 43 54 43 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 129 131 129 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pc</italic>
###xml 260 292 260 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003671.s001">Supplementary online material S1</xref>
###xml 260 308 260 308 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="supplementary-material" rid="pone.0003671.s001">Supplementary online material S1</xref> (SOM) section 1</bold>
###xml 349 351 349 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pc</italic>
###xml 505 507 505 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pc</italic>
###xml 521 530 521 530 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1b</bold>
###xml 521 530 521 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003671-g001"><bold>Figure 1b</bold></xref>
###xml 610 619 610 619 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1b</bold>
###xml 610 619 610 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003671-g001"><bold>Figure 1b</bold></xref>
###xml 624 632 624 632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003671.s002">Table S1</xref>
###xml 624 632 624 632 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="supplementary-material" rid="pone.0003671.s002">Table S1</xref></bold>
###xml 655 664 655 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003671-g001">Figure 1b</xref>
###xml 717 719 717 719 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pc</italic>
###xml 896 898 896 898 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pc</italic>
###xml 933 935 933 935 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ro</italic>
###xml 938 947 938 947 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1b</bold>
###xml 938 947 938 947 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003671-g001"><bold>Figure 1b</bold></xref>
###xml 1025 1027 1025 1027 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ro</italic>
###xml 1053 1055 1053 1055 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ro</italic>
###xml 1178 1182 1178 1182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Antia1">[66]</xref>
###xml 1216 1218 1216 1218 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ro</italic>
###xml 1321 1332 1321 1332 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 1478 1489 1478 1489 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 1498 1500 1498 1500 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ro</italic>
###xml 960 965 <span type="species:ncbi:9606">human</span>
###xml 969 974 <span type="species:ncbi:9606">human</span>
###xml 1361 1364 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
We examined the population-level impact of CCL3L1-CCR5 GRG status within the rubric of an epidemiologic parameter, designated as Pc, as well as other relevant epidemiologic parameters. The description of these parameters and their derivations are described in Supplementary online material S1 (SOM) section 1. The critical vaccination proportion or Pc is an important estimate of the fraction of the population that must be vaccinated successfully to eradicate an epidemic. The mathematical components of Pc are shown in Figure 1b along with the possible points at which GRG status might affect this estimate (Figure 1b and Table S1 online). The model in Figure 1b shows that the GRGs might influence the estimate of Pc primarily by influencing infectiousness and susceptibility, and possibly by also affecting responses to vaccines that rely on the generation of CMI. One important component of Pc is the basic reproductive number (Ro) (Figure 1b). Effective human-to-human transmission of an infectious agent requires that Ro should exceed one, where Ro is the average number of secondary infections arising from one infected individual in a completely susceptible population [66]. Thus, the epidemic threshold is Ro = 1, above which the disease spreads and below which it eventually dies out. Given that variations in CCL3L1-CCR5 are associated with altered HIV susceptibility and/or communicability, we first used highly conservative assumptions to model the effects of the CCL3L1-CCR5 GRGs on Ro.
###end p 17
###begin p 18
###xml 185 194 185 194 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2a</bold>
###xml 185 194 185 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003671-g002"><bold>Figure 2a</bold></xref>
###xml 399 403 399 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Gonzalez4">[20]</xref>
###xml 627 636 627 636 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2a</bold>
###xml 627 636 627 636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003671-g002"><bold>Figure 2a</bold></xref>
###xml 691 693 691 693 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ro</italic>
###xml 718 727 718 727 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2b</bold>
###xml 718 727 718 727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003671-g002"><bold>Figure 2b</bold></xref>
###xml 761 763 761 763 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ro</italic>
###xml 879 888 879 888 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2b</bold>
###xml 879 888 879 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003671-g002"><bold>Figure 2b</bold></xref>
###xml 1093 1095 1093 1095 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ro</italic>
###xml 1111 1120 1111 1120 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2a</bold>
###xml 1111 1120 1111 1120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003671-g002"><bold>Figure 2a</bold></xref>
###xml 1125 1134 1125 1134 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2b</bold>
###xml 1125 1134 1125 1134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003671-g002"><bold>Figure 2b</bold></xref>
###xml 891 894 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 896 899 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
We modeled sexual transmission, and based on the GRG status of the infected and uninfected partner pair, the overall population can be divided into nine partner-pair population groups (Figure 2a). We determined the distribution of the GRG-defined partner pairs from the prevalence (parenthesis) of the low (50%), moderate (42%) and high (8%) GRG status in a large US-based cohort of mixed ethnicity [20]. Assuming random mixing among individuals in the general population, the GRG-defined partner pairs in which one member has a low and moderate GRG constituted nearly 88% of the population, i.e., group numbers 1, 2, 4 and 5 (Figure 2a). In all but one (group #1) of these nine groups, the Ro was greater than unity (Figure 2b). In partner-pair groups 1 to 9, Ro increased in a step-wise manner, and this increase was mostly dependent on the GRG status of the infected partner (Figure 2b). HIV+/HIV- partner pairs defined by a low-low, moderate-moderate, and high-high GRG status - that is, partner-pair population groups 1, 5 and 9 - were associated with the least, intermediate and highest Ro, respectively (Figure 2a and Figure 2b).
###end p 18
###begin title 19
###xml 44 55 44 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 140 145 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Modeling studies assessing the influence of CCL3L1-CCR5 genotypes on epidemiological parameters relevant to the outgrowth and prevention of HIV-1.
###end title 19
###begin p 20
###xml 40 51 40 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 212 216 212 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Gonzalez4">[20]</xref>
###xml 400 402 400 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ro</italic>
###xml 652 654 652 654 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pc</italic>
###xml 711 713 711 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pc</italic>
###xml 807 809 807 809 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pc</italic>
###xml 871 873 871 873 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pc</italic>
###xml 999 1001 999 1001 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pc</italic>
###xml 1091 1099 1091 1099 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003671.s003">Table S2</xref>
###xml 187 190 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
(a) Nine population groups based on the CCL3L1-CCR5 GRG status of sexual partners. The estimated proportions (prevalence) of the GRGs in the general population are based on data from the HIV-positive WHMC cohort [20]. L, M, and H denote low, moderate, and high GRG status, respectively. The color codes shown are used to illustrate the nine population groups (Grp) in panels b to g. (b) Estimates of Ro for the nine color-coded GRG-defined population groups. (c) Simulated epidemic growth in GRG-defined population groups. Methods are in SOM, section 1.9 online. (d to f) Attributable fractions (AF, panel d), critical response time (CRT, panel e) and Pc (f) in the nine population groups. The calculations for Pc (f) assume a vaccine efficacy of 50%. (g) Influence of varying vaccine efficacy estimates on Pc in the nine GRG-defined population. groups shown in panel a. Pc values greater than unity (dashed horizontal line) indicate the point at which repeated mass vaccination might be necessary. Pc for population group #1 was zero. Additional data relevant to these studies are shown in Table S2 online.
###end p 20
###begin p 21
###xml 6 8 6 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ro</italic>
###xml 154 156 154 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ro</italic>
###xml 339 350 339 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 363 372 363 372 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2c</bold>
###xml 363 372 363 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003671-g002"><bold>Figure 2c</bold></xref>
###xml 633 642 633 642 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2c</bold>
###xml 633 649 633 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003671-g002"><bold>Figure 2c</bold>, inset</xref>
###xml 976 985 976 985 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2c</bold>
###xml 976 985 976 985 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003671-g002"><bold>Figure 2c</bold></xref>
###xml 1052 1054 1052 1054 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ro</italic>
###xml 1142 1151 1142 1151 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2c</bold>
###xml 1142 1151 1142 1151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003671-g002"><bold>Figure 2c</bold></xref>
###xml 1263 1272 1263 1272 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2c</bold>
###xml 1263 1272 1263 1272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003671-g002"><bold>Figure 2c</bold></xref>
###xml 1394 1403 1394 1403 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2c</bold>
###xml 1394 1403 1394 1403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003671-g002"><bold>Figure 2c</bold></xref>
###xml 1331 1334 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Since Ro is a fundamental concept in explaining the emergence and persistence of epidemics, we next determined whether these GRG-dependent differences in Ro might also translate into differences in the rate of epidemic growth (the number of new infected cases per unit of time) in partner-pair population groups categorized based on their CCL3L1-CCR5 GRG status (Figure 2c). In a model that assumes a closed population, the simulated overall trajectory of the epidemic growth took approximately ten years to emerge and, without an influx of a susceptible pool of individuals, predictably, the simulated epidemic eventually died out (Figure 2c, inset). However, the simulated trajectories for each of the nine GRG-defined population groups were strikingly different in three ways: the time point at which an increase in epidemic growth became evident; the extent of epidemic growth, i.e., the proportion of subjects infected; and the duration for which the epidemic persisted (Figure 2c). These differences in the trajectories in large part tracked the Ro estimates and were predictably highly dependent on the infecting partner's GRG status (Figure 2c). Remarkably, the epidemic growth was negligible when the infected partner possessed a low GRG (groups 1 to 3; Figure 2c). Conversely, the epidemic outgrowth was maximal when the HIV-infected partner pair possessed a high GRG (groups 7 to 9; Figure 2c).
###end p 21
###begin p 22
###xml 154 163 154 163 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2d</bold>
###xml 154 163 154 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003671-g002"><bold>Figure 2d</bold></xref>
###xml 342 351 342 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003671-g002">Figure 2c</xref>
###xml 521 530 521 530 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2d</bold>
###xml 521 530 521 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003671-g002"><bold>Figure 2d</bold></xref>
###xml 654 658 654 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Gonzalez4">[20]</xref>
###xml 660 664 660 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Dolan1">[53]</xref>
###xml 861 872 861 872 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 1067 1070 1067 1070 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Anderson1">[1]</xref>
###xml 1072 1075 1072 1075 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Blower1">[2]</xref>
###xml 1077 1081 1077 1081 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Johnston1">[41]</xref>
###xml 1083 1087 1083 1087 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Desrosiers1">[67]</xref>
###xml 1089 1093 1089 1093 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-AbuRaddad1">[68]</xref>
###xml 1095 1099 1095 1099 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Amirfar1">[69]</xref>
###xml 1213 1222 1213 1222 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2a</bold>
###xml 1213 1222 1213 1222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003671-g002"><bold>Figure 2a</bold></xref>
###xml 1505 1514 1505 1514 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2e</bold>
###xml 1505 1514 1505 1514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003671-g002"><bold>Figure 2e</bold></xref>
###xml 1063 1066 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The nine GRG-defined population groups together contributed approximately 45% to the overall epidemic growth (as estimated by attributable fraction (AF); Figure 2d). However, the relative contribution of each of the nine GRG-defined population groups to the overall epidemic varied significantly (0 to 13%). Consistent with findings shown in Figure 2c, the highest AFs, and consequently the greatest contribution to the overall epidemic, were due to infected subjects possessing the moderate or high GRGs (groups 4 to 9; Figure 2d), i.e., those who are more likely to be infectious because of higher VLs or have greater susceptibility to acquiring virus [20], [53]. This implies that a reduction in the population-level viral load - for example, by a vaccine or HAART - will have the greatest benefit in abating the spread of the epidemic when applied to these CCL3L1-CCR5 genetically-defined subjects which agrees with the growing view that a vaccine that can modify disease course by lowering the viral load setpoint holds promise in curbing epidemic growth of HIV [1], [2], [41], [67], [68], [69]. The impact of this strategy could be large, since these subjects make up nearly 50% of the infected population (Figure 2a). Additionally, the critical response time (CRT), defined as the time interval within which the number of epidemic cases remains stationary (so that interventions implemented within CRT may be the most effective or the least costly), varied across the GRGs from 2.59 to 15.3 years (Figure 2e). Thus, these modeling data suggest that the time available to implement control measures against spread of the infection may also be highly dependent on the GRGs.
###end p 22
###begin p 23
###xml 80 91 80 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 116 118 116 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pc</italic>
###xml 159 161 159 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pc</italic>
###xml 214 216 214 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ro</italic>
###xml 245 246 245 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 263 264 263 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</italic>
###xml 267 276 267 276 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1b</bold>
###xml 267 276 267 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003671-g001"><bold>Figure 1b</bold></xref>
###xml 279 282 279 282 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOM</bold>
###xml 284 295 284 295 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">section 1.5</bold>
###xml 367 378 367 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 486 488 486 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pc</italic>
###xml 521 523 521 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ro</italic>
###xml 698 700 698 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pc</italic>
###xml 747 749 747 749 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ro</italic>
###xml 751 760 751 760 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2f</bold>
###xml 751 760 751 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003671-g002"><bold>Figure 2f</bold></xref>
###xml 763 765 763 765 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pc</italic>
###xml 874 876 874 876 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pc</italic>
###xml 1101 1110 1089 1098 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2a</bold>
###xml 1101 1110 1089 1098 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003671-g002"><bold>Figure 2a</bold></xref>
###xml 1155 1157 1143 1145 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pc</italic>
Finally, using highly conservative assumptions, we considered the effect of the CCL3L1-CCR5 GRGs on the estimate of Pc. In sensitivity analyses, we found that Pc was much more sensitive to changes in the values of Ro than those of vaccine take (t) or durability (d) (Figure 1b) (SOM, section 1.5 online). This implies that, regardless of the effects of variations in CCL3L1-CCR5 on the eventual immune responses induced by a vaccine, the bulk of the effects of these genetic factors on Pc will be due to their effects on Ro. Consistent with this, in a mathematical model in which the values of vaccine take and durability were held constant, and assuming a vaccine that has an efficacy of 50%, the Pc estimates increased with increasing values of Ro (Figure 2f). Pc was less than unity in the population groups in which the infected partner possessed a low GRG. Remarkably, Pc was zero when the both the infected and uninfected partner pair possessed a low GRG, suggesting that from a purely theoretical perspective this population group, which constitutes approximately30% of the overall population (Figure 2a), may not require vaccination. By contrast, Pc was greater than unity in the six population groups in which the infected partner possessed a moderate or high GRG.
###end p 23
###begin p 24
###xml 18 20 18 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pc</italic>
###xml 120 122 120 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pc</italic>
###xml 211 220 211 220 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2g</bold>
###xml 211 220 211 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003671-g002"><bold>Figure 2g</bold></xref>
###xml 393 402 393 402 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2g</bold>
###xml 393 402 393 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003671-g002"><bold>Figure 2g</bold></xref>
Since in practice Pc cannot be greater than unity, this implies that to contain the epidemic in population groups where Pc>1 might require repeated immunizations, or vaccination with a more efficacious vaccine (Figure 2g). For example, our models indicate that a vaccine with an efficacy of more than 70% would be required to confer protection by mass vaccination in population groups 5 to 9 (Figure 2g).
###end p 24
###begin title 25
###xml 32 35 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Impact of GRGs on assessment of HIV vaccine efficacy
###end title 25
###begin p 26
###xml 82 93 82 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 188 191 188 191 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOM</bold>
###xml 193 202 193 202 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">section 2</bold>
###xml 205 214 205 214 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3a</bold>
###xml 205 214 205 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003671-g003"><bold>Figure 3a</bold></xref>
###xml 282 293 282 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 929 938 917 926 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3a</bold>
###xml 929 938 917 926 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003671-g003"><bold>Figure 3a</bold></xref>
###xml 1060 1069 1048 1057 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3b</bold>
###xml 1060 1069 1048 1057 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003671-g003"><bold>Figure 3b</bold></xref>
###xml 455 458 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
We considered that failure to account for the transmission-influencing effects of CCL3L1-CCR5 genotypes might mask true efficacy estimates of a vaccine that partially blocks transmission (SOM, section 2). Figure 3a models the effects of misallocating subjects with respect to their CCL3L1-CCR5 GRG status in the placebo or vaccine arms of a trial with a preventive vaccine which has an efficacy of 50%. This mathematical model is relatively impervious to HIV incidence and trial size number; and it predicted that, depending on its direction, misallocation will result in the over- or underestimation of the vaccine's true efficacy. For example, in a trial of 500 subjects, for a vaccine that has a 50% efficacy, misallocation of only 25 (5%) subjects has an estimated efficacy of 44% (95% confidence interval (CI) of 41%-45%), and this is a relative error of approximately12% (95% CI of 10%-18%) from the true vaccine estimate (Figure 3a). This effect of GRG-dependent misallocation is magnified when a vaccine with lower efficacy is considered in the model (Figure 3b). These effects of misallocation might be further compounded by the fact that vaccine-induced CMI might wane faster in subjects who possess the moderate and high GRGs.
###end p 26
###begin title 27
###xml 13 24 13 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
Influence of CCL3L1-CCR5 GRG status on vaccine efficacy.
###end title 27
###begin p 28
###xml 123 134 123 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
(a) Estimated vaccine efficacy as a function of the percentage of subjects that are misallocated (m) with respect to their CCL3L1-CCR5 genotype across the placebo or vaccine trial arms. The model is for a preventive vaccine that has a true efficacy of 50%. The upper line in this plot depicts estimated vaccine efficacy as a function of misallocation of subjects with a low GRG towards the vaccine arm, resulting in a fallacious increase in the estimated vaccine efficacy. The lower line depicts the converse situation, i.e., misallocation of subjects with a low GRG towards the placebo arm, resulting in a fallacious decrease in the estimated vaccine efficacy. (b) Plots depict the difference (relative error) between the true and estimated vaccine efficacy as a percentage of the true vaccine efficacy for varying values of m. Methods are described in SOM, section 2.
###end p 28
###begin title 29
Discussion
###end title 29
###begin p 30
###xml 109 112 109 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Cohen1">[3]</xref>
###xml 114 118 114 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-AsamoahOdei1">[30]</xref>
###xml 120 124 120 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Buve1">[31]</xref>
###xml 126 130 126 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Pepin1">[32]</xref>
###xml 132 136 132 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Ferry1">[33]</xref>
###xml 138 142 138 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Buve2">[34]</xref>
###xml 144 148 144 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Buve3">[35]</xref>
###xml 150 154 150 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Mokili1">[36]</xref>
###xml 156 160 156 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Mulanga1">[37]</xref>
###xml 162 166 162 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-KinoshitaMoleka1">[38]</xref>
###xml 588 592 588 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Pepin1">[32]</xref>
###xml 700 704 700 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Ferry1">[33]</xref>
###xml 706 710 706 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Buve2">[34]</xref>
###xml 987 991 987 991 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Mulanga1">[37]</xref>
###xml 993 997 993 997 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-KinoshitaMoleka1">[38]</xref>
###xml 1008 1012 1008 1012 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Gonzalez1">[13]</xref>
###xml 1014 1018 1014 1018 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Gonzalez2">[16]</xref>
###xml 1020 1024 1020 1024 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Gonzalez4">[20]</xref>
###xml 1026 1030 1026 1030 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-He1">[70]</xref>
###xml 1042 1046 1042 1046 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Winkler2">[18]</xref>
###xml 1048 1052 1048 1052 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-OBrien1">[24]</xref>
###xml 1054 1058 1054 1058 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Kaslow1">[26]</xref>
###xml 1060 1064 1060 1064 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Pepin1">[32]</xref>
###xml 1066 1070 1066 1070 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Sullivan1">[71]</xref>
###xml 1072 1076 1072 1076 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Schliekelman1">[72]</xref>
###xml 1078 1082 1078 1082 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Sabeti1">[73]</xref>
###xml 1084 1088 1084 1088 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Novembre1">[74]</xref>
###xml 1090 1094 1090 1094 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Sirugo1">[75]</xref>
###xml 1378 1382 1378 1382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Sullivan1">[71]</xref>
###xml 1446 1458 1446 1454 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5-&#916;32</italic>
###xml 1603 1607 1599 1603 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5</italic>
###xml 1631 1637 1627 1633 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1</italic>
###xml 27 30 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 683 686 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 826 829 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 899 902 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1283 1286 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1663 1666 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The global distribution of HIV among populations is highly heterogeneous, even in a continent such as Africa [3], [30], [31], [32], [33], [34], [35], [36], [37], [38]. Many factors are likely to account for this heterogeneity, including viral factors, sexual behavior patterns, sexually transmitted infection, poverty, male circumcision status, unrest and wars, urbanization, and other social and economic reasons. However, the results of a large ecologic study indicated that the social, behavioral, economic and political confounders cannot in themselves account for this heterogeneity [32]. For example, sexual behaviors between cities in Africa with a high and low prevalence of HIV were similar [33], [34]. Additionally, despite extensive poverty, war and breakdown of health care systems, the steady-state prevalence of HIV in the Democratic Republic of Congo, a country near the epicenter of HIV, has remained remarkably stable and much lower than that of its neighboring nations [37], [38]. Thus, we [13], [16], [20], [70] and others [18], [24], [26], [32], [71], [72], [73], [74], [75] have proposed that in addition to viral and other factors, biologic factors such as the genetic make-up of populations might contribute to this heterogeneity in the global distribution of HIV. One of these previous studies used mathematical modeling to substantiate this possibility [71]; however, the analysis was confined to the contribution of the CCR5-Delta32 mutation, which is restricted to individuals of European descent. By contrast, we have modeled the effects of a wider range of polymorphisms in CCR5 and the copy number of CCL3L1 that are determinants of HIV-AIDS susceptibility.
###end p 30
###begin p 31
###xml 103 112 103 112 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2c</bold>
###xml 103 119 103 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003671-g002"><bold>Figure 2c</bold>, inset</xref>
###xml 126 137 126 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 270 279 270 279 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2c</bold>
###xml 270 279 270 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003671-g002"><bold>Figure 2c</bold></xref>
###xml 369 378 369 378 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2c</bold>
###xml 369 378 369 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003671-g002"><bold>Figure 2c</bold></xref>
###xml 480 486 480 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1</italic>
###xml 516 520 516 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5</italic>
###xml 798 802 798 802 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Deeks1">[76]</xref>
###xml 843 847 843 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Dolan1">[53]</xref>
###xml 999 1001 999 1001 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ro</italic>
###xml 1279 1283 1279 1283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Desrosiers1">[67]</xref>
###xml 1310 1313 1310 1313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Anderson1">[1]</xref>
###xml 1315 1318 1315 1318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Blower1">[2]</xref>
###xml 1320 1324 1320 1324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-AbuRaddad1">[68]</xref>
###xml 1326 1330 1326 1330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Amirfar1">[69]</xref>
###xml 89 92 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 417 422 <span type="species:ncbi:9606">human</span>
###xml 584 589 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 643 646 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 793 796 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1015 1018 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1020 1023 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1166 1169 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Our findings indicated that under the umbrella of an overall trajectory of the simulated HIV epidemic (Figure 2c, inset), the CCL3L1-CCR5 GRG-defined partner pair population groups discriminate for several distinct subtrajectories with different shapes and time-scales (Figure 2c). Of these subtrajectories, only a few appear to be critical in sustaining the epidemic (Figure 2c). Conversely, these data suggest that human populations that are enriched for low GRGs, i.e., a high CCL3L1 gene dose and nondetrimental CCR5 genotypes, might be relatively protected against the spread of HIV-1. Bolstering this possibility, we recently found that HIV-infected individuals who maintained very low viral loads and who were disease free despite not receiving therapy (elite or viremic controllers of HIV) [76] were selectively enriched for a low GRG [53]. Given the importance of the VL in transmission, it is likely that such subjects will transmit virus at very low rates. Thus, the data indicating that Ro is lowest in HIV+/HIV- partner pairs in which the transmitting partner has a low-risk GRG status suggest that vaccines directed towards reducing infectivity of the HIV+ host may play an important role in halting epidemic spread. Underscoring this, findings from animal studies [67] and mathematical modeling [1], [2], [68], [69] support the hope that imperfect, T-cell based disease-modifying, i.e., therapeutic vaccines, by reducing plasma viral load at the population level might abate the epidemic.
###end p 31
###begin p 32
###xml 70 81 70 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 576 580 576 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Vidal1">[77]</xref>
###xml 582 586 582 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Keele1">[78]</xref>
###xml 588 592 588 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-VanHeuverswyn1">[79]</xref>
###xml 836 840 836 840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Keele1">[78]</xref>
###xml 842 846 842 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-VanHeuverswyn1">[79]</xref>
###xml 1271 1275 1271 1275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Ndembi1">[80]</xref>
###xml 1277 1281 1277 1281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Zekeng1">[81]</xref>
###xml 1759 1763 1759 1763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Wolfe1">[82]</xref>
###xml 1886 1890 1886 1890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Mahieux1">[83]</xref>
###xml 1898 1909 1898 1909 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 2283 2287 2283 2287 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5</italic>
###xml 2316 2320 2316 2320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Gonzalez1">[13]</xref>
###xml 2322 2326 2322 2326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Gonzalez2">[16]</xref>
###xml 2328 2332 2328 2332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Mummidi1">[84]</xref>
###xml 2354 2360 2354 2360 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1</italic>
###xml 2401 2409 2401 2409 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4</bold>
###xml 2401 2409 2401 2409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003671-g004"><bold>Figure 4</bold></xref>
###xml 2473 2477 2473 2477 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5</italic>
###xml 2492 2496 2492 2496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Gonzalez1">[13]</xref>
###xml 2498 2502 2498 2502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Mummidi1">[84]</xref>
###xml 2504 2508 2504 2508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Wooding1">[85]</xref>
###xml 2520 2525 2520 2525 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L</italic>
###xml 2539 2547 2539 2547 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4</bold>
###xml 2539 2547 2539 2547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003671-g004"><bold>Figure 4</bold></xref>
###xml 2549 2553 2549 2553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Gonzalez4">[20]</xref>
###xml 2620 2631 2620 2631 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 2887 2893 2887 2893 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1</italic>
###xml 2898 2902 2898 2902 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5</italic>
###xml 3081 3085 3081 3085 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Rutjens1">[86]</xref>
###xml 3119 3130 3119 3130 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 144 147 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 284 289 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 434 437 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 570 575 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 628 657 <span type="species:ncbi:11723">simian immunodeficiency virus</span>
###xml 659 662 <span type="species:ncbi:11723?0.9432672590567327">SIV</span>
###xml 670 676 <span type="species:ncbi:9606">humans</span>
###xml 737 748 <span type="species:ncbi:9598">chimpanzees</span>
###xml 1141 1144 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1145 1148 <span type="species:ncbi:11723?0.9432672590567327">SIV</span>
###xml 1321 1324 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1371 1381 <span type="species:ncbi:9598">chimpanzee</span>
###xml 1514 1519 <span type="species:ncbi:9606">human</span>
###xml 1630 1657 <span type="species:ncbi:39101">simian T-lymphotropic virus</span>
###xml 1695 1701 <span type="species:ncbi:9606">humans</span>
###xml 1710 1715 <span type="species:ncbi:9606">human</span>
###xml 1862 1873 <span type="species:ncbi:9598">chimpanzees</span>
###xml 1986 1991 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 2428 2439 <span type="species:ncbi:9598">chimpanzees</span>
###xml 2734 2739 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 2821 2824 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 2921 2931 <span type="species:ncbi:9598">chimpanzee</span>
###xml 3021 3024 <span type="species:ncbi:11723?0.9432672590567327">SIV</span>
###xml 3077 3080 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Thus, the results of our modeling data indicate that there might be a CCL3L1-CCR5-dependent biological basis for interpopulation differences in HIV prevalence. We illustrate this concept further with the example of Pygmies, a distinct population in Central Africa. The high number of HIV-1 subtypes cocirculating, the high intrasubtype diversity, and the high numbers of possible recombinant viruses as well as different unclassified HIV strains are all in agreement with an old and mature epidemic in Central Africa, and suggest that these regions are the epicenter of HIV-1 [77], [78], [79]. The cross-species transmission of simian immunodeficiency virus (SIV)cpz to humans is now thought to have occurred by exposure to the blood of chimpanzees infected with SIVcpz during hunting and butchering of these primates in Central Africa [78], [79]. The Pygmies, one of the oldest ethnic groups in this area, have lived in Central Africa for more than 20,000 years. These hunter-gatherers have been, and continue to be, frequently and directly exposed to nonhuman primate blood during hunting, slaughtering and cooking. However, surprisingly, HIV/SIV infection in Pygmies is rare and occurs mainly after contact with Bantus rather than from contact with nonhuman primates ([80], [81] and references therein). The rarity of HIV infection via cross-species transmission from chimpanzee to Pygmies contrasts with the fact that documented zoonosis of other viruses has occurred into this population. Data indicates that human T-lymphotropic virus (HTLV)-1 diversity appears to have resulted from multiple cross-species transmissions of simian T-lymphotropic virus (STLVs)-1 following contract between humans and non-human primate species infected with STLV species [82]. Strikingly, Pygmies harbor a heterogeneous HTLV-1 strain, which is very similar to the STLV-1 in chimpanzees (STLV-1cpz) [83]. Might CCL3L1-CCR5 genetic constitution help explain in part why cross-species transmission of HIV-1 has been rarely observed in Pygmies despite evidence of other viral zoonosis? In this respect, it is noteworthy that compared to other African populations that reside in geographical proximity (e.g., non-Pygmy Cameroonians), Pygmies have an even higher frequency of the protective ancestral CCR5 haplotype designated as HHA [13], [16], [84] and the gene dose of CCL3L1 is highest in this isolated population (Figure 4). Strikingly, all chimpanzees possess the protective ancestral CCR5 haplotype HHA [13], [84], [85] and a high CCL3L copy number (Figure 4) [20]. Based on these observations, we conjecture whether this distinct CCL3L1-CCR5 genetic makeup of Pygmies might explain the observed relative resistance to cross-species transfer of HIV-1 but susceptibility to other viral infections, as well as the lower prevalence of HIV relative to those of neighboring populations. By analogy, the CCL3L1 and CCR5 genetic makeup of chimpanzee might afford this nonhuman primate species protection against disease induced by natural SIV infection as well as to experimental infection with HIV [86]. The strikingly monomorphic host CCL3L1-CCR5 genetic constitution of Pygmies contrasts with the extensive viral heterogeneity prevalent in Central Africa.
###end p 32
###begin title 33
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1</italic>
###xml 27 31 27 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5</italic>
CCL3L1 copy number (a) and CCR5 HHA haplotype frequency (b) in Pygmies (N = 51) and Cameroonians (N = 372).
###end title 33
###begin p 34
###xml 33 37 33 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5</italic>
###xml 78 84 78 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1</italic>
###xml 113 118 113 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L</italic>
###xml 118 122 118 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Gonzalez4">[20]</xref>
###xml 22 32 <span type="species:ncbi:9598">chimpanzee</span>
###xml 72 77 <span type="species:ncbi:9606">human</span>
###xml 88 98 <span type="species:ncbi:9598">chimpanzee</span>
The prevalence of the chimpanzee CCR5 HHA haplotype and the ortholog of human CCL3L1 in chimpanzee designated as CCL3L[20], is also shown (N = 83). Error bars in panel a denote 95% confidence interval.
###end p 34
###begin p 35
###xml 16 24 16 24 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003671-g002">Figure 2</xref>
###xml 55 66 55 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 202 204 202 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pc</italic>
###xml 264 275 264 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 608 612 608 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Zimet1">[87]</xref>
###xml 773 777 773 777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Blower2">[88]</xref>
###xml 861 865 861 865 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Andre1">[89]</xref>
###xml 128 131 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 223 226 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 228 231 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 296 299 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 393 396 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 681 684 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 799 802 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The findings in Figure 2 collectively suggest that the CCL3L1-CCR5 GRGs play a role in determining not only the dynamics of the HIV epidemic but also in the design of prevention programs. We found that Pc was >1 in several HIV+/HIV- partner pairs defined by their CCL3L1-CCR5 genotype and that a HIV vaccine with an efficacy of lower than 70% might be ineffective in controlling the spread of HIV in these genetically-defined population groups. This threshold of 70% is also relevant in the context of three prior observations. First, vaccine acceptability might be highest when the efficacy is at least 70% [87]; second, studies that have modeled the effects of a live-attenuated HIV vaccine have shown that efficacy is best matched with safety around this same threshold [88]; and third, most non-HIV vaccines in use today have an efficacy between 70 and 90% [89].
###end p 35
###begin p 36
###xml 47 58 47 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 254 258 254 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Johnston1">[41]</xref>
###xml 491 495 491 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Johnston1">[41]</xref>
###xml 497 501 497 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Klausner1">[90]</xref>
###xml 503 507 503 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Garber1">[91]</xref>
###xml 509 513 509 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Nabel1">[92]</xref>
###xml 1114 1117 1114 1117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Gilbert1">[6]</xref>
###xml 1119 1123 1119 1123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-AIDS1">[93]</xref>
###xml 1148 1159 1148 1159 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 1258 1259 1258 1259 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1333 1334 1333 1334 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 137 140 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 180 185 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 324 327 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 564 570 <span type="species:ncbi:9606">humans</span>
###xml 590 593 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 875 878 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1075 1078 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1198 1201 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Our models consider the possible impact of the CCL3L1-CCR5 GRGs on the evaluation of efficacy estimates of a sterilizing or prophylactic HIV vaccine. First-generation prophylactic HIV-1 vaccines are unlikely to provide complete protection from infection [41]. Consequently, there is a thrust to evaluate candidate imperfect HIV/AIDS vaccines, including those that can stimulate cell-mediated immune responses that are directed at controlling viral replication after acquisition of infection [41], [90], [91], [92]. Several of these vaccines are being evaluated in humans (). In addition to HIV acquisition, surrogate endpoints currently under consideration for assessment of such disease-modifying vaccines can be categorized as (a) immunologic, e.g., maintenance of the CD4+ T-cell counts; (b) virologic, e.g., decreased VL set-point; (c) clinical, e.g., reduced numbers of HIV-infected vaccinated subjects requiring antiretroviral treatment and/or developing clinical disease; and (d) epidemiological, e.g., lower sexual transmission rate by vaccinated subjects who become HIV-infected subsequent to vaccination [6], [93]. However, variations in CCL3L1-CCR5 by impacting on (i) risk of acquiring HIV infection, (ii) viral load, (iii) rate and extent of CD4+ T cell depletion, and (iii) time from seroconversion to thresholds of CD4+ T cell counts at which antiviral therapy is initiated might confound the assessment of the currently used surrogates of vaccine endpoints.
###end p 36
###begin p 37
###xml 120 131 120 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 361 365 361 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Poland1">[94]</xref>
###xml 553 557 553 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Cohen2">[39]</xref>
###xml 559 563 559 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Moore1">[40]</xref>
###xml 565 569 565 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Johnston1">[41]</xref>
###xml 571 575 571 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Fauci1">[42]</xref>
###xml 577 581 577 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Walker1">[43]</xref>
###xml 583 587 583 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Steinbrook1">[44]</xref>
###xml 731 735 731 735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Moore1">[40]</xref>
###xml 1336 1340 1336 1340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Kernan1">[95]</xref>
###xml 1384 1395 1384 1395 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 1859 1870 1859 1870 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 2094 2098 2094 2098 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5</italic>
###xml 2174 2178 2174 2178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Gonzalez1">[13]</xref>
###xml 2180 2184 2180 2184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Winkler2">[18]</xref>
###xml 2487 2498 2487 2498 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 2710 2716 2710 2716 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L-</italic>
###xml 2721 2727 2721 2727 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL4L-</italic>
###xml 2881 2884 2881 2884 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA</italic>
###xml 2942 2946 2942 2946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Luo1">[96]</xref>
###xml 1020 1023 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1058 1070 <span type="species:ncbi:9606">participants</span>
###xml 1420 1432 <span type="species:ncbi:9606">participants</span>
###xml 2208 2211 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 2459 2462 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Additionally, the finding that misallocation of subjects based on their genetic constitution, modeled here according to CCL3L1-CCR5 genotypes, might result in fallacious estimates of a vaccine's efficacy, has relevance for several reasons. First, it is possible that confounding due biological factors may influence both the evaluation and outcome of a vaccine [94]. This is best illustrated by the results of the STEP trial where antibody titers to Adenovirus 5 appear to have confounded the outcome and the interpretation of the efficacy of the virus [39], [40], [41], [42], [43], [44]. We have suggested that these higher titers could be due to an underlying host genetic constitution that may convey a "stronger immune system" [40]. Additionally, after the failure of two vaccine trials there is a need to rapidly evaluate vaccine candidates, especially in smaller numbers of individuals before conducting larger and more expensive trials. Although our modeling is based on a randomized trial which is impervious to HIV incidence and the number of trial participants, the confounding due to misallocation of favorable or unfavorable genotypes in trial arms may be important in three scenarios - trials with small sample sizes; interim analysis of large trials; and trials that demonstrate equivalence between two candidate vaccines [95]. At least in these situations the baseline CCL3L1-CCR5 genotyping of the trial participants might have relevance so as to either resort to a stratified randomization protocol or to post-allocation adjustment for the potential influence of the genotypes on vaccine efficacy. However it is also important to note that large vaccine evaluation trials (e.g., recent STEP trial) are invariably a composite of subjects from several different geographically disparate clinical sites, and consequently, failure to account for CCL3L1-CCR5 genotype at these smaller sites in subjects with different racial backgrounds might result in confounding of a larger multicenter trial. This might be an important point to consider in light of two observations. First, the CCR5 genotypes that influence AIDS susceptibility differ according to ethnicity [13], [18]. Second, the high-risk HIV-negative cohorts likely to be recruited for vaccine trials might be enriched for genotypes that confer protection. Hence, if a vaccine were to be tested in such subjects it might be difficult to differentiate between the protective effects of the HIV vaccine versus those of CCL3L1-CCR5 genotype or other protective genotypes. Two observations support this possibility: (i) in a cohort of high-risk female sex workers from South Africa, we found an enrichment of subjects with high copy numbers of CCL3L- and CCL4L-containing segmental duplications (Ramsuran et al, unpublished data); and (ii) a previous study found that there is an enrichment over time of protective HLA genotypes in a cohort of East African female sex workers [96].
###end p 37
###begin p 38
###xml 158 161 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 299 302 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 604 609 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Thus, taken together, our findings suggest that the inherent variability among individuals and, by extension, among populations, in host genes that influence HIV-AIDS susceptibility might be an important but hitherto underestimated biological challenge to contend with in the quest for an effective HIV-AIDS vaccine. Extending the notion of pharmacogenomics, which links host genetic determinants to variable responses to pharmacologic agents, we suggest that vaccinogenomics is an equally important concept to consider in the design and evaluation of vaccines, not only for established scourges such as HIV-1, tuberculosis, and malaria, but also for emerging infectious diseases.
###end p 38
###begin title 39
Materials and Methods
###end title 39
###begin p 40
###xml 30 41 30 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 549 553 549 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Gonzalez1">[13]</xref>
###xml 555 559 555 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Gonzalez4">[20]</xref>
###xml 561 565 561 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Dolan1">[53]</xref>
###xml 762 770 762 770 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table S1</bold>
###xml 762 770 762 770 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003671.s002"><bold>Table S1</bold></xref>
###xml 67 70 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 126 129 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 461 464 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 672 675 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Our modeling studies used the CCL3L1-CCR5 genotyping data from the HIV-positive subjects from the Department of Defense (DoD) HIV Natural History Study (NHS) cohort followed at Wilford Hall Medical Center (WHMC) and more recently at the Brooke Army Medical Center (BAMC), San Antonio, TX. The studied population is the local component of a prospective multisite observational cohort from the United States Military's Tri-Service AIDS Clinical Consortium (TACC) HIV Natural History Study. Extensive details of this cohort has been provided elsewhere [13], [20], [53]. Unidentified cast-off blood from subjects participating in training at Lackland AFB, TX was used for the HIV-negative control population. The definitions of all the model parameters are shown in Table S1.
###end p 40
###begin title 41
###xml 0 2 0 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pc</italic>
Pc estimate
###end title 41
###begin p 42
###xml 154 157 154 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Anderson1">[1]</xref>
###xml 159 162 159 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003671-Blower1">[2]</xref>
###xml 199 201 199 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pc</italic>
###xml 399 401 399 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ro</italic>
###xml 403 404 403 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">e</italic>
###xml 409 410 409 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f</italic>
###xml 145 148 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
For our analyses, we used the conceptual and mathematical frameworks developed previously for the epidemiological context of vaccination against HIV-AIDS [1], [2]. These models rely on computing the Pc, which is extensively used as an estimate of the critical proportion of the population- or cohort-based vaccination coverage required to limit an epidemic. This estimate has three main components (Ro, e and f) which are shown in the equation below.
###end p 42
###begin p 43
###xml 0 2 0 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pc</italic>
###xml 26 28 26 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pc</italic>
###xml 49 51 49 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ro</italic>
###xml 230 231 230 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">e</italic>
###xml 264 265 264 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f</italic>
###xml 473 482 473 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003671-g001">Figure 1b</xref>
###xml 503 504 503 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f</italic>
###xml 566 568 566 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ro</italic>
###xml 570 571 570 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">e</italic>
###xml 576 578 576 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pc</italic>
###xml 591 592 591 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f</italic>
###xml 619 652 619 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003671.s001">Supplementary Online Materials S1</xref>
###xml 619 658 619 658 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="supplementary-material" rid="pone.0003671.s001">Supplementary Online Materials S1</xref> (SOM)</bold>
###xml 660 671 660 671 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Section 1.1</bold>
Pc = [1-(1/Ro)]/ef. Thus, Pc is a function of i) Ro, the basic reproduction number which provides a measure of the average number of secondary infections generated by one primary case of infection in a susceptible population; ii) e, the vaccine efficacy; and iii) f, the fraction of vaccinated subjects in whom the vaccine effect does not wane over the period of infectiousness, i.e., the duration of protection afforded by the vaccine. These three parameters are shown in Figure 1b, and we have termed f in this figure as vaccine durability. The relationship among Ro, e and Pc for a fixed f is shown in the figure in Supplementary Online Materials S1 (SOM), Section 1.1.
###end p 43
###begin p 44
###xml 63 71 63 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003671-g001">Figure 1</xref>
###xml 104 115 104 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 237 238 237 238 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</sub>
###xml 236 238 236 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R<sub>o</sub></italic>
###xml 241 242 241 242 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</sub>
###xml 240 242 240 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R<sub>o</sub></italic>
###xml 268 279 268 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 453 456 453 456 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOM</bold>
###xml 458 477 458 477 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Section 1.1 and 1.2</bold>
###xml 523 534 523 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 591 594 591 594 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOM</bold>
###xml 596 616 596 616 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sections 1.3 and 1.4</bold>
###xml 796 799 796 799 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOM</bold>
###xml 801 812 801 812 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">section 1.5</bold>
###xml 895 898 895 898 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOM</bold>
###xml 900 920 900 920 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sections 1.6 and 1.7</bold>
###xml 922 934 922 934 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">respectively</bold>
###xml 1053 1064 1053 1064 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 151 154 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
We used a deterministic, compartmentalized mathematical model (Figure 1) to assess the influence of the CCL3L1-CCR5 GRGs on the population dynamics of HIV infection. The dynamics were based on the estimation of the reproductive number, Ro. Ro was computed within each CCL3L1-CCR5 GRG-defined population strata as well as for the overall population, and detailed methods employed and the assumptions underlying the mathematical model are provided in the SOM, Section 1.1 and 1.2. We accounted for the possible effect of the CCL3L1-CCR5 GRGs on vaccine efficacy and durability as discussed in SOM, sections 1.3 and 1.4, respectively. To ensure generalizability of the results of our modeling studies we also conducted sensitivity analyses on the model parameters, the results of which are shown in SOM, section 1.5. Attributable fraction and critical response time were calculated as described in SOM, sections 1.6 and 1.7, respectively. In our mathematical modeling, we assumed that the risk behavior and probability of circumcision is not influenced by CCL3L1-CCR5 GRG status.
###end p 44
###begin title 45
###xml 41 47 41 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1</italic>
###xml 52 56 52 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5</italic>
Influence of the unequal distribution of CCL3L1 and CCR5 genotypes in trial arms on the estimates of vaccine efficacy in preventive trials
###end title 45
###begin p 46
###xml 267 270 267 270 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOM</bold>
###xml 272 281 272 281 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">section 2</bold>
###xml 145 148 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
We simulated a typical randomized two-arm trial design to examine the influence of the genotypic imbalance across trial arms on the estimates of HIV vaccine efficacy. The full derivation of the mathematical model used for estimating this influence is provided in the SOM, section 2.
###end p 46
###begin title 47
Supporting Information
###end title 47
###begin p 48
###xml 56 61 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Role of CCL3L1-CCR5 genotypes in the epidemic spread of HIV-1 and evaluation of vaccine efficac.
###end p 48
###begin p 49
(0.57 MB DOC)
###end p 49
###begin p 50
Click here for additional data file.
###end p 50
###begin p 51
Summary of parameters used to model the influence of CCL3L1-CCR5 GRGs on epidemiological endpoints. Note, the inclusion of the parameters of vaccine efficacy and durability were included on a proof-of-principle basis for vaccines which rely in part on CMI for their effects.
###end p 51
###begin p 52
(0.03 MB DOC)
###end p 52
###begin p 53
Click here for additional data file.
###end p 53
###begin p 54
###xml 82 91 82 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003671-g002">Figure 2a</xref>
###xml 250 258 250 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003671.s002">Table S1</xref>
Group, indicates subdivision of the population into 9 groups based on their GRGs (Figure 2a). Estimated frequency indicates the proportion of the population groups from data derived from the WHMC cohort. The parameters are described in Supplementary Table S1.
###end p 54
###begin p 55
(0.05 MB DOC)
###end p 55
###begin p 56
Click here for additional data file.
###end p 56
###begin p 57
We thank Scott Wegner and other members of IDCRP for critical support of this work; G. Crawford and S. S. Ahuja for programmatic support at UTHSCSA; M. Mamtani for constructive criticisms; B. Shah for outstanding dedication to the graphic work; and A. S. Ahuja for forbearance.
###end p 57
###begin title 58
References
###end title 58
###begin article-title 59
###xml 44 47 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Potential public health impact of imperfect HIV type 1 vaccines.
###end article-title 59
###begin article-title 60
###xml 26 29 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Forecasting the future of HIV epidemics: the impact of antiretroviral therapies & imperfect vaccines.
###end article-title 60
###begin article-title 61
###xml 41 46 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The spread, treatment, and prevention of HIV-1: evolution of a global pandemic.
###end article-title 61
###begin article-title 62
###xml 44 79 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group.
###end article-title 62
###begin article-title 63
###xml 15 20 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 78 83 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda.
###end article-title 63
###begin article-title 64
###xml 32 60 <span type="species:ncbi:12721">human immunodeficiency virus</span>
What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials.
###end article-title 64
###begin article-title 65
###xml 23 28 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study.
###end article-title 65
###begin article-title 66
###xml 14 19 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene.
###end article-title 66
###begin article-title 67
###xml 24 29 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk.
###end article-title 67
###begin article-title 68
###xml 31 36 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS).
###end article-title 68
###begin article-title 69
Genetic acceleration of AIDS progression by a promoter variant of CCR5.
###end article-title 69
###begin article-title 70
Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC).
###end article-title 70
###begin article-title 71
###xml 14 19 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Race-specific HIV-1 disease-modifying effects associated with CCR5 haplotypes.
###end article-title 71
###begin article-title 72
Influence of CCR5 promoter haplotypes on AIDS progression in African-Americans.
###end article-title 72
###begin article-title 73
###xml 129 137 <span type="species:ncbi:9606">children</span>
###xml 161 189 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Concordance between the CC chemokine receptor 5 genetic determinants that alter risks of transmission and disease progression in children exposed perinatally to human immunodeficiency virus.
###end article-title 73
###begin article-title 74
###xml 102 107 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Global survey of genetic variation in CCR5, RANTES, and MIP-1alpha: impact on the epidemiology of the HIV-1 pandemic.
###end article-title 74
###begin article-title 75
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels.
###end article-title 75
###begin article-title 76
Patterns of ethnic diversity among the genes that influence AIDS.
###end article-title 76
###begin article-title 77
###xml 60 65 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
AIDS restriction HLA allotypes target distinct intervals of HIV-1 pathogenesis.
###end article-title 77
###begin article-title 78
###xml 66 71 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility.
###end article-title 78
###begin article-title 79
###xml 75 80 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
A whole-genome association study of major determinants for host control of HIV-1.
###end article-title 79
###begin article-title 80
###xml 57 62 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1.
###end article-title 80
###begin article-title 81
###xml 62 67 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Polymorphisms of CUL5 are associated with CD4+ T cell loss in HIV-1 infected individuals.
###end article-title 81
###begin article-title 82
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human genes that limit AIDS.
###end article-title 82
###begin article-title 83
###xml 27 30 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Impact of host genetics on HIV disease progression and treatment: new conflicts on an ancient battleground.
###end article-title 83
###begin article-title 84
###xml 57 60 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Influence of host genetic variation on susceptibility to HIV type 1 infection.
###end article-title 84
###begin article-title 85
###xml 29 32 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Host genetic determinants of HIV pathogenesis: an immunologic perspective. Immune correlates of protection, activation and exhaustion. .
###end article-title 85
###begin article-title 86
###xml 50 78 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Host factors associated with outcome from primary human immunodeficiency virus-1 infection. .
###end article-title 86
###begin article-title 87
Detecting AIDS restriction genes: from candidate genes to genome-wide association discovery.
###end article-title 87
###begin article-title 88
###xml 0 3 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
HIV prevalence and trends in sub-Saharan Africa: no decline and large subregional differences.
###end article-title 88
###begin article-title 89
###xml 25 30 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The spread and effect of HIV-1 infection in sub-Saharan Africa.
###end article-title 89
###begin article-title 90
###xml 87 90 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
From the Old World to the New World: an ecologic study of population susceptibility to HIV infection.
###end article-title 90
###begin article-title 91
###xml 108 111 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Comparison of key parameters of sexual behaviour in four African urban populations with different levels of HIV infection.
###end article-title 91
###begin article-title 92
###xml 72 75 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The multicentre study on factors determining the differential spread of HIV in four African cities: summary and conclusions.
###end article-title 92
###begin article-title 93
###xml 0 3 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 57 60 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
HIV epidemics in Africa: what explains the variations in HIV prevalence?
###end article-title 93
###begin article-title 94
###xml 14 17 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The spread of HIV in Africa.
###end article-title 94
###begin article-title 95
###xml 60 63 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Political and socioeconomic instability: how does it affect HIV? A case study in the Democratic Republic of Congo.
###end article-title 95
###begin article-title 96
###xml 18 21 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 93 98 <span type="species:ncbi:9606">women</span>
Low prevalence of HIV and other selected sexually transmitted infections in 2004 in pregnant women from Kinshasa, the Democratic Republic of the Congo.
###end article-title 96
###begin article-title 97
AIDS research. Promising AIDS vaccine's failure leaves field reeling.
###end article-title 97
###begin article-title 98
###xml 5 8 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
AIDS/HIV. A STEP into darkness or light?
###end article-title 98
###begin article-title 99
###xml 3 6 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
An HIV vaccine-evolving concepts.
###end article-title 99
###begin article-title 100
###xml 0 3 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
HIV vaccine research: the way forward.
###end article-title 100
###begin article-title 101
Toward an AIDS vaccine.
###end article-title 101
###begin article-title 102
One step forward, two steps back-will there ever be an AIDS vaccine?
###end article-title 102
###begin article-title 103
###xml 23 28 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease.
###end article-title 103
###begin article-title 104
###xml 32 35 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Biology of CCR5 and its role in HIV infection and treatment.
###end article-title 104
###begin article-title 105
###xml 35 40 <span type="species:ncbi:9606">human</span>
###xml 111 114 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
LD78beta, a non-allelic variant of human MIP-1alpha (LD78alpha), has enhanced receptor interactions and potent HIV suppressive activity.
###end article-title 105
###begin article-title 106
###xml 49 54 <span type="species:ncbi:9606">human</span>
Gene copy number regulates the production of the human chemokine CCL3-L1.
###end article-title 106
###begin article-title 107
###xml 14 19 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Enhanced anti-HIV-1 activity of CC-chemokine LD78beta, a non-allelic variant of MIP-1alpha/LD78alpha.
###end article-title 107
###begin article-title 108
###xml 96 131 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 147 152 <span type="species:ncbi:9606">human</span>
The LD78beta isoform of MIP-1alpha is the most potent CC-chemokine in inhibiting CCR5-dependent human immunodeficiency virus type 1 replication in human macrophages.
###end article-title 108
###begin article-title 109
###xml 159 164 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Diverging binding capacities of natural LD78beta isoforms of macrophage inflammatory protein-1alpha to the CC chemokine receptors 1, 3 and 5 affect their anti-HIV-1 activity and chemotactic potencies for neutrophils and eosinophils.
###end article-title 109
###begin article-title 110
###xml 71 76 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The LD78beta isoform of MIP-1alpha is the most potent CCR5 agonist and HIV-1-inhibiting chemokine.
###end article-title 110
###begin article-title 111
###xml 60 63 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms.
###end article-title 111
###begin article-title 112
###xml 101 131 <span type="species:ncbi:11676">human immunodeficiency virus 1</span>
Reduced ability of newborns to produce CCL3 is associated with increased susceptibility to perinatal human immunodeficiency virus 1 transmission.
###end article-title 112
###begin article-title 113
###xml 8 15 <span type="species:ncbi:9606">infants</span>
###xml 54 57 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
African infants' CCL3 gene copies influence perinatal HIV transmission in the absence of maternal nevirapine.
###end article-title 113
###begin article-title 114
###xml 60 65 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 92 95 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Copy number variations of CCL3L1 and long-term prognosis of HIV-1 infection in asymptomatic HIV-infected Japanese with hemophilia.
###end article-title 114
###begin article-title 115
###xml 68 73 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
CCL3L1 Variable Gene Copy Number Influence on the Susceptibility to HIV-1/AIDS Among Estonian Intravenous Drug User 15th Conference on Retroviruses and Opportunistic Infections Abstract 296
###end article-title 115
###begin article-title 116
###xml 95 100 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals.
###end article-title 116
###begin article-title 117
Association of the CCR5delta32 mutation with improved response to antiretroviral therapy.
###end article-title 117
###begin article-title 118
Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy.
###end article-title 118
###begin article-title 119
Host genetic influences on highly active antiretroviral therapy efficacy and AIDS-free survival.
###end article-title 119
###begin article-title 120
###xml 44 49 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 122 127 <span type="species:ncbi:9606">women</span>
Host CCL3L1 gene copy number in relation to HIV-1-specific CD4+ and CD8+ T-cell responses and viral load in South African women.
###end article-title 120
###begin article-title 121
###xml 61 66 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
CCL3L1-CCR5 genotype improves the assessment of AIDS Risk in HIV-1-infected individuals.
###end article-title 121
###begin article-title 122
###xml 9 14 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 56 61 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Rates of HIV-1 Transmission per Coital Act, by Stage of HIV-1 Infection, in Rakai, Uganda.
###end article-title 122
###begin article-title 123
###xml 23 28 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Immunologic control of HIV-1.
###end article-title 123
###begin article-title 124
The role of evolution in the emergence of infectious diseases.
###end article-title 124
###begin article-title 125
Prospects for an AIDS vaccine.
###end article-title 125
###begin article-title 126
###xml 77 80 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Analytic insights into the population level impact of imperfect prophylactic HIV vaccines.
###end article-title 126
###begin article-title 127
###xml 45 48 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 60 63 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 90 95 <span type="species:ncbi:9606">women</span>
###xml 100 107 <span type="species:ncbi:9606">infants</span>
Modeling the impact of a partially effective HIV vaccine on HIV infection and death among women and infants in South Africa.
###end article-title 127
###begin article-title 128
###xml 66 71 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 121 124 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Duffy antigen receptor for chemokines mediates trans-infection of HIV-1 from red blood cells to target cells and affects HIV-AIDS susceptibility.
###end article-title 128
###begin article-title 129
###xml 63 66 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 100 103 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The coreceptor mutation CCR5Delta32 influences the dynamics of HIV epidemics and is selected for by HIV.
###end article-title 129
###begin article-title 130
###xml 36 39 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Natural selection and resistance to HIV.
###end article-title 130
###begin article-title 131
The case for selection at CCR5-Delta32.
###end article-title 131
###begin article-title 132
###xml 42 45 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The geographic spread of the CCR5 Delta32 HIV-resistance allele.
###end article-title 132
###begin article-title 133
Genetic studies of African populations: an overview on disease susceptibility and response to vaccines and therapeutics.
###end article-title 133
###begin article-title 134
###xml 0 28 <span type="species:ncbi:12721">Human immunodeficiency virus</span>
Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy.
###end article-title 134
###begin article-title 135
###xml 24 59 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 61 66 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 148 153 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Unprecedented degree of human immunodeficiency virus type 1 (HIV-1) group M genetic diversity in the Democratic Republic of Congo suggests that the HIV-1 pandemic originated in Central Africa.
###end article-title 135
###begin article-title 136
###xml 0 10 <span type="species:ncbi:9598">Chimpanzee</span>
###xml 50 55 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Chimpanzee reservoirs of pandemic and nonpandemic HIV-1.
###end article-title 136
###begin article-title 137
###xml 15 18 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The Origins of HIV and Implications for the Global Epidemic.
###end article-title 137
###begin article-title 138
###xml 0 3 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
HIV type 1 infection in Pygmy hunter gatherers is from contact with Bantu rather than from nonhuman primates.
###end article-title 138
###begin article-title 139
###xml 10 13 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 14 17 <span type="species:ncbi:11723?0.9432672590567327">SIV</span>
Update on HIV/SIV infections in Cameroon.
###end article-title 139
###begin article-title 140
Emergence of unique primate T-lymphotropic viruses among central African bushmeat hunters.
###end article-title 140
###begin article-title 141
###xml 41 75 <span type="species:ncbi:11908">human T-cell leukemia virus type 1</span>
Molecular epidemiology of 58 new African human T-cell leukemia virus type 1 (HTLV-1) strains: identification of a new and distinct HTLV-1 molecular subtype in Central Africa and in Pygmies.
###end article-title 141
###begin article-title 142
###xml 13 18 <span type="species:ncbi:9606">human</span>
###xml 27 32 <span type="species:ncbi:9606">human</span>
###xml 279 284 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 289 318 <span type="species:ncbi:11723">simian immunodeficiency virus</span>
Evolution of human and non-human primate CC chemokine receptor 5 gene and mRNA. Potential roles for haplotype and mRNA diversity, differential haplotype-specific transcriptional activity, and altered transcription factor binding to polymorphic nucleotides in the pathogenesis of HIV-1 and simian immunodeficiency virus.
###end article-title 142
###begin article-title 143
###xml 44 49 <span type="species:ncbi:9606">human</span>
###xml 54 64 <span type="species:ncbi:9598">chimpanzee</span>
Contrasting effects of natural selection on human and chimpanzee CC chemokine receptor 5.
###end article-title 143
###begin article-title 144
###xml 62 73 <span type="species:ncbi:9598">chimpanzees</span>
Lentivirus infections and mechanisms of disease resistance in chimpanzees.
###end article-title 144
###begin article-title 145
###xml 45 48 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Vaccine characteristics and acceptability of HIV immunization among adolescents.
###end article-title 145
###begin article-title 146
###xml 16 19 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Live attenuated HIV vaccines: predicting the tradeoff between efficacy and safety.
###end article-title 146
###begin article-title 147
Vaccinology: past achievements, present roadblocks and future promises.
###end article-title 147
###begin article-title 148
###xml 32 35 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Medicine. The need for a global HIV vaccine enterprise.
###end article-title 148
###begin article-title 149
Prospects for an AIDS vaccine: three big questions, no easy answers.
###end article-title 149
###begin article-title 150
Challenges and opportunities for development of an AIDS vaccine.
###end article-title 150
###begin article-title 151
Heterogeneity in vaccine immune response: the role of immunogenetics and the emerging field of vaccinomics.
###end article-title 151
###begin article-title 152
Stratified randomization for clinical trials.
###end article-title 152
###begin article-title 153
###xml 53 58 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 124 129 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Rapid Selection for HLA Alleles that Protect Against HIV-1 Infection Correlates Significantly to the Declining Incidence of HIV-1 in an East African Sex Worker Population.
###end article-title 153
###begin p 154
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 154
###begin p 155
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
###xml 88 91 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 441 444 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Funding: This work was supported by the Veterans Administration (VA) Center on AIDS and HIV infection of the South Texas Veterans Health Care System, and a MERIT (R37046326) and other awards (AI043279 and MH069270) from the NIH to S.K.A. S.K.A. is also supported by a VA MERIT award and is a recipient of the Elizabeth Glaser Scientist Award and the Burroughs Wellcome Clinical Scientist Award in Translational Research. Support for the DoD HIV Natural History Study cohort and staff involved in this work was provided by the Infectious Disease Clinical Research Program (IDCRP) of the Uniformed Services University of the Health Sciences (USUHS), of which the Tri-Service AIDS Clinical Consortium (TACC) is a component. The IDCRP is a Department of Defense tri-service program executed through USUHS and the Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF), in collaboration with HHS/NIH/NIAID/DCR through Interagency Agreement HU0001-05-2-0011. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The opinions or assertions contained herein are the private views of the authors, and are not to be construed as official, or as reflecting the views of the Departments of the Army, Navy, Air Force, or the Department of Defense.
###end p 155

